HepaRegeniX GmbH | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Home
Companies
HepaRegeniX GmbH

BRIEF

published on 10/22/2024 at 10:35, 29 days 23 hours ago

HepaRegeniX Appoints Dr. Martin Bonde as New Chair of the Board

HepaRegeniX HRX-215 Liver Regeneration Martin Bonde Biotech Leadership
BRIEF

published on 10/22/2024 at 10:35, 29 days 23 hours ago

HepaRegeniX nomme le Dr Martin Bonde au poste de nouveau président du conseil d'administration

HepaRegeniX HRX-215 Régénération Du Foie Martin Bonde Leadership En Biotechnologie
PRESS RELEASE

published on 10/22/2024 at 10:30, 29 days 23 hours ago

HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board
HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board, succeeding Elias Papatheodorou who becomes CEO. Preparation for clinical trials ongoing

Clinical Trials HepaRegeniX Liver Regeneration Chair Of The Board Dr. Martin Bonde
BRIEF

published on 07/10/2024 at 09:05, 4 months 11 days ago

HepaRegeniX Raises €15 Million to Advance Liver Regeneration Drug

Clinical Trials HepaRegeniX HRX-215 Liver Regeneration Series C Funding
BRIEF

published on 07/10/2024 at 09:05, 4 months 11 days ago

HepaRegeniX lève 15 millions d'euros pour faire progresser un médicament contre la régénération du foie

Essais Cliniques HepaRegeniX HRX-215 Régénération Du Foie Financement De Série C
PRESS RELEASE

published on 07/10/2024 at 09:00, 4 months 11 days ago

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
HepaRegeniX raises €15 million Series C round led by Vesalius Biocapital IV to advance clinical development of HRX-215 for liver regeneration, appoints Elias Papatheodorou as CEO and Dr. Linda Greenbaum as CMO

Clinical Development HepaRegeniX HRX-215 Liver Regeneration €15 Million Series C Round
BRIEF

published on 03/14/2024 at 16:20, 8 months 6 days ago

HepaRegeniX Announces Promising Data for Liver Disease Treatment with MKK4 Inhibitor HRX-215

Clinical Study HepaRegeniX HRX-215 Liver Regeneration MKK4 Inhibitor
BRIEF

published on 03/14/2024 at 16:20, 8 months 6 days ago

HepaRegeniX annonce des données prometteuses pour le traitement des maladies du foie avec l'inhibiteur MKK4 HRX-215

Étude Clinique HepaRegeniX HRX-215 Régénération Du Foie Inhibiteur MKK4
PRESS RELEASE

published on 03/14/2024 at 16:15, 8 months 6 days ago

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
HepaRegeniX publishes data on MKK4 inhibitor HRX-215 for acute and chronic liver diseases in Cell journal, showing safety, liver regeneration, and potential in oncological liver surgery and transplantation

Régénération HepaRegeniX MKK4 Inhibitor Liver Diseases Oncological Surgery

Accesswire

Published on 11/21/2024 at 09:00, 35 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 10 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 35 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 35 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 34 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 35 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 35 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 20 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 26 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 37 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 37 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 37 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 28 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 15 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE